Joan Merrill to Placebos
This is a "connection" page, showing publications Joan Merrill has written about Placebos.
Connection Strength
0.337
-
Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020 10 01; 59(10):2930-2938.
Score: 0.183
-
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct; 62(10):3077-87.
Score: 0.092
-
Appropriate management of antiphospholipid-related pregnancy in women without lupus who have low titer autoantibodies. Curr Rheumatol Rep. 2001 Aug; 3(4):269-70.
Score: 0.049
-
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec; 46(12):3251-8.
Score: 0.013